MeSH term
Frequency | Condition_Probility | Humans | 132 | 0.0 |
Hybridomas | 3 | 2.0 |
In Vitro | 6 | 0.0 |
Research Support, Non-U.S. Gov't | 104 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Animals | 75 | 0.0 |
Antigens, CD1/genetics/*metabolism | 5 | 83.0 |
Cell Line | 17 | 0.0 |
Hela Cells | 5 | 0.0 |
Mice | 51 | 0.0 |
Antigens, CD1/*metabolism | 10 | 31.0 |
Cell Differentiation | 3 | 0.0 |
Dendritic Cells/*immunology | 3 | 1.0 |
Killer Cells, Natural/*immunology | 29 | 5.0 |
Models, Immunological | 7 | 3.0 |
Neoplasms/immunology | 5 | 9.0 |
Research Support, U.S. Gov't, P.H.S. | 71 | 0.0 |
T-Lymphocytes/*immunology | 12 | 0.0 |
Cells, Cultured | 18 | 0.0 |
*Cytotoxicity, Immunologic | 6 | 1.0 |
Female | 20 | 0.0 |
Lymphocyte Culture Test, Mixed | 3 | 0.0 |
Adult | 14 | 0.0 |
Aged | 9 | 0.0 |
Comparative Study | 10 | 0.0 |
Dendritic Cells/*metabolism | 2 | 3.0 |
Immunohistochemistry | 6 | 0.0 |
Microscopy, Electron | 3 | 0.0 |
Middle Aged | 10 | 0.0 |
T-Lymphocytes/metabolism | 2 | 0.0 |
Cytokines/biosynthesis | 5 | 0.0 |
Cytotoxicity Tests, Immunologic | 3 | 0.0 |
Immunophenotyping | 11 | 0.0 |
Interferon Type II/biosynthesis | 6 | 1.0 |
Killer Cells, Natural/immunology | 11 | 2.0 |
*Lectins, C-Type | 4 | 2.0 |
Lymphocyte Activation | 11 | 0.0 |
Th1 Cells/*immunology | 2 | 1.0 |
Antigens, CD56/metabolism | 2 | 7.0 |
Membrane Glycoproteins/metabolism | 3 | 0.0 |
U937 Cells | 2 | 0.0 |
Endocytosis | 3 | 0.0 |
Killer Cells, Natural/*physiology | 2 | 4.0 |
Antigens, CD1/chemistry/*immunology/metabolism | 2 | 100.0 |
Molecular Sequence Data | 20 | 0.0 |
Molecular Structure | 2 | 0.0 |
Receptors, Antigen, T-Cell, alpha-beta/immunology | 3 | 4.0 |
Amino Acid Sequence | 17 | 0.0 |
Antigens, CD1/immunology | 2 | 18.0 |
Ligands | 7 | 0.0 |
Th2 Cells/*immunology | 2 | 1.0 |
Antigens, CD1/*immunology | 17 | 48.0 |
Cattle | 2 | 0.0 |
Dendritic Cells/cytology/*immunology | 2 | 3.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Cytotoxicity, Immunologic/*immunology | 2 | 4.0 |
Galactosylceramides/*pharmacology | 4 | 57.0 |
Interferon Type II/secretion | 2 | 1.0 |
Jurkat Cells | 2 | 0.0 |
Receptors, Antigen, T-Cell/immunology | 2 | 1.0 |
Recombinant Proteins/pharmacology | 3 | 0.0 |
T-Lymphocyte Subsets/drug effects/*immunology | 2 | 7.0 |
Transfection | 11 | 0.0 |
Tumor Cells, Cultured | 13 | 0.0 |
Antigens, CD1/genetics | 2 | 50.0 |
Interferon Type II/metabolism | 3 | 1.0 |
Killer Cells, Natural/drug effects/*immunology | 3 | 8.0 |
Mice, Inbred NOD | 4 | 1.0 |
Mice, Inbred Strains | 2 | 0.0 |
Mice, Mutant Strains | 2 | 0.0 |
Base Sequence | 13 | 0.0 |
Galactosylceramides/pharmacology | 3 | 42.0 |
Interleukin-4/secretion | 2 | 4.0 |
Male | 12 | 0.0 |
Mice, Knockout | 10 | 0.0 |
Antibodies, Monoclonal/pharmacology | 4 | 0.0 |
Cytotoxicity, Immunologic | 6 | 0.0 |
Interferon Type II/pharmacology | 2 | 0.0 |
Interleukin-2/pharmacology | 2 | 0.0 |
Mice, Inbred BALB C | 5 | 0.0 |
Mice, Inbred C57BL | 14 | 0.0 |
Phenotype | 2 | 0.0 |
Spleen/cytology | 3 | 1.0 |
Thymus Gland/cytology | 2 | 2.0 |
Antigens, CD1/*genetics | 10 | 71.0 |
Cell Differentiation/immunology | 3 | 0.0 |
Cell Lineage/immunology | 2 | 6.0 |
Flow Cytometry | 17 | 0.0 |
Antigen Presentation/immunology | 3 | 3.0 |
Glycolipids/immunology | 2 | 25.0 |
Killer Cells, Natural/cytology/*immunology | 3 | 10.0 |
T-Lymphocytes/cytology/*immunology | 2 | 1.0 |
Blotting, Western | 5 | 0.0 |
Cell Differentiation/genetics/immunology | 2 | 2.0 |
Cell Line, Transformed | 2 | 0.0 |
Molecular Weight | 5 | 0.0 |
Phytohemagglutinins/pharmacology | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Biological Markers | 5 | 0.0 |
Killer Cells, Natural/*metabolism | 3 | 5.0 |
B-Lymphocytes/immunology | 3 | 0.0 |
Galactosylceramides/*immunology | 3 | 42.0 |
Receptors, Antigen, T-Cell, alpha-beta/*immunology | 5 | 9.0 |
Cell Lineage | 2 | 0.0 |
Cloning, Molecular | 7 | 0.0 |
Gene Library | 2 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Thymus Gland/cytology/immunology/metabolism | 2 | 16.0 |
Intestinal Mucosa/*immunology | 6 | 6.0 |
Antibodies, Monoclonal/immunology | 5 | 0.0 |
*Antigen Presentation | 10 | 6.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Antigens, CD/*immunology | 2 | 0.0 |
Disease Models, Animal | 3 | 0.0 |
Mice, SCID | 3 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 2 | 0.0 |
Histocompatibility Antigens Class II/analysis | 2 | 1.0 |
Mice, Inbred DBA | 2 | 0.0 |
English Abstract | 2 | 0.0 |
Antigens, CD/biosynthesis | 2 | 0.0 |
Killer Cells, Natural/*immunology/metabolism | 4 | 10.0 |
Lymphocyte Activation/immunology | 4 | 0.0 |
Membrane Glycoproteins/biosynthesis | 2 | 1.0 |
T-Lymphocyte Subsets/*immunology/metabolism | 3 | 6.0 |
Antigens, CD1/biosynthesis/*immunology | 2 | 100.0 |
Clone Cells | 4 | 0.0 |
Monocytes/immunology | 2 | 0.0 |
Receptors, Antigen, T-Cell, alpha-beta/*biosynthesis | 2 | 28.0 |
Protein Isoforms/genetics | 2 | 0.0 |
Intestines/*immunology | 2 | 11.0 |
T-Lymphocytes/*immunology/metabolism | 2 | 1.0 |
Immunization | 3 | 0.0 |
T-Lymphocytes/immunology | 6 | 0.0 |
Interleukin-4/biosynthesis | 4 | 2.0 |
Lymphocyte Activation/*immunology | 2 | 0.0 |
Antigens, CD1/*physiology | 3 | 30.0 |
Histocompatibility Antigens Class I/genetics/immunology | 2 | 13.0 |
Lymphocyte Activation/genetics | 2 | 2.0 |
Organ Specificity/immunology | 2 | 6.0 |
Antibody Specificity | 2 | 0.0 |
Antigens, CD1/chemistry/*metabolism | 3 | 100.0 |
Receptors, Antigen, T-Cell, alpha-beta/analysis | 2 | 4.0 |
Thymus Gland/immunology | 2 | 3.0 |
Protein Binding | 5 | 0.0 |
Antigens, CD1/metabolism | 5 | 12.0 |
T-Lymphocytes/*metabolism | 2 | 0.0 |
Antigens, Bacterial/chemistry/metabolism | 2 | 100.0 |
Autoimmunity | 3 | 2.0 |
Models, Molecular | 4 | 0.0 |
Protein Conformation | 3 | 0.0 |
Conserved Sequence | 3 | 0.0 |
DNA/genetics | 3 | 0.0 |
Immunoglobulin Variable Region/genetics | 2 | 1.0 |
T-Lymphocyte Subsets/*immunology | 11 | 2.0 |
Interleukin-4/immunology | 2 | 3.0 |
*Lymphocyte Activation | 7 | 0.0 |
Serine Endopeptidases/metabolism | 2 | 1.0 |
Th1 Cells/immunology | 5 | 2.0 |
Aged, 80 and over | 3 | 0.0 |
Cohort Studies | 2 | 0.0 |
Cell Line, Tumor | 3 | 0.0 |
DNA Primers | 3 | 0.0 |
Lipids/*metabolism | 2 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Chromosomes, Human, Pair 1 | 2 | 0.0 |
Genetic Markers | 2 | 0.0 |
Karyotyping | 2 | 0.0 |
Rats/*genetics | 2 | 3.0 |
Antigens, CD1/genetics/*immunology | 2 | 66.0 |
Caco-2 Cells | 2 | 0.0 |
Intestinal Mucosa/cytology/*immunology | 3 | 20.0 |
Signal Transduction | 2 | 0.0 |
Antigen Presentation/*immunology | 7 | 7.0 |
Binding, Competitive | 3 | 0.0 |
Glycolipids/*immunology | 2 | 12.0 |
Kinetics | 2 | 0.0 |
Solubility | 3 | 0.0 |
Lipids/*immunology | 3 | 37.0 |
Th2 Cells/immunology | 4 | 2.0 |
CD8-Positive T-Lymphocytes/*immunology | 2 | 0.0 |
Histocompatibility Antigens Class I/immunology | 2 | 1.0 |
Antigens, CD1/*genetics/metabolism | 2 | 100.0 |
Pregnancy | 2 | 0.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Antigen Presentation | 5 | 1.0 |
Precipitin Tests | 5 | 0.0 |
*Antigens, CD1 | 2 | 100.0 |
Antigens, CD8 | 2 | 0.0 |
CD4-Positive T-Lymphocytes/immunology | 2 | 0.0 |
*Cytotoxicity, Immunologic/drug effects | 2 | 7.0 |
CHO Cells | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Glycosylation | 2 | 0.0 |
Hamsters | 2 | 0.0 |
Tyrosine/chemistry | 2 | 1.0 |
Mice, Transgenic | 3 | 0.0 |
Lymphocyte Activation/drug effects | 2 | 0.0 |
Lymphocyte Count | 4 | 0.0 |
Case-Control Studies | 3 | 0.0 |
Rats | 5 | 0.0 |
Restriction Mapping | 3 | 0.0 |
Antigens, CD8/immunology | 2 | 2.0 |
Major Histocompatibility Complex/immunology | 2 | 4.0 |
Genetic Vectors | 2 | 0.0 |
Antigens, CD1 | 10 | 10.0 |
Infection/immunology | 2 | 6.0 |
Protein Transport/physiology | 2 | 1.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Gene Expression | 2 | 0.0 |
Antigens, CD/*genetics | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
beta 2-Microglobulin/metabolism | 2 | 2.0 |
Epithelial Cells | 2 | 0.0 |
Epithelium/immunology | 3 | 2.0 |
T-Lymphocyte Subsets/immunology | 2 | 0.0 |
Antigens, CD/immunology | 2 | 0.0 |
Antigens, CD1/biosynthesis/*metabolism | 2 | 66.0 |
Spectrum Analysis, Mass | 2 | 0.0 |
Galactosylceramides/immunology | 3 | 42.0 |
Interferon Type II/immunology/metabolism | 2 | 14.0 |
Antigens, CD1/*chemistry | 2 | 100.0 |
T-Lymphocyte Subsets/cytology/*immunology/metabolism | 2 | 22.0 |
*Gene Expression Regulation | 2 | 0.0 |
Heat-Shock Proteins 70/*physiology | 2 | 40.0 |
Antigens, CD1/physiology | 2 | 33.0 |
Antigens, CD1/analysis | 2 | 2.0 |
Cytokines/immunology | 3 | 2.0 |
